Clinical trials: Immunoglobulin
Neuroblastoma, High-Risk
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
This is a phase I study. The purpose of this study is to see if it is safe and feasible to give the participant cyclophosphamide (a type of chemotherapy), natural killer (NK) cells, and an antibody called Hu3F8 as a treatment for…
- Trial name
- NCT02650648
- Testing
- cyclophosphamide, NK cells, hu3F8
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy.
- Trial name
- NCT06235918
- Testing
- Tislelizumab, Nab-paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiang Lu
Advanced Cancer
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
This study evaluated the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-A317 in participants with advanced tumors.
- Trial name
- NCT02407990
- Testing
- BGB-A317
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 451 people
- Sponsor
- BeiGene
Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy
IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies
This study will enroll patients with small fiber neuropathy (SFN). The study will look at an intravenous immunoglobulin (IVIG) called Panzyga.
- Conditions
- Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy, Immune-Mediated Neuropathy
- Trial name
- NCT04153422
- Testing
- Panzyga IVIG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Health
Secondary Immune Deficiency Disorder
Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig
Patients with chronic lymphocytic leukemia (CLL) are at increased risk of infections as compared to age matched controls, with infections being a major cause of morbidity and mortality.
- Trial name
- NCT03730129
- Testing
- Hizentra
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rochester General Hospital
Healthy
Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.
There is a need to understand antibody responses following SARS-COV-2 infection and subsequent vaccination.
- Trial name
- C-VELVET (NCT04954937)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- NHS Blood and Transplant
Meningitis, Meningococcemia
Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults
This study was designed to generate data for the assessment of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) when given to adults aged 18 to 55 years.
- Trial name
- NCT00772629
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Lupus Nephritis, Immunoglobulin A Nephropathy
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition…
- Trial name
- SANCTUARY (NCT04564339)
- Testing
- Ravulizumab, Background Therapy
- Where
- 64 sites in United States, Australia and 10 more
- Volunteers
- 123 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Relapsed or Refractory Multiple Myeloma
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds.
- Trial name
- NCT04735575
- Testing
- EMB-06
- Where
- 10 sites in Australia, China
- Volunteers
- 40 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Healthy Male Volunteers
A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose (SAD) administration of E6011 in Japanese healthy volunteers.
- Trial name
- NCT01731275
- Testing
- E6011
- Where
- Japan
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
MOGAD, Migraine
Headache Prevalence and Phenotype in Myelin Oligodendrocyte Glycoprotein Antibody -Associated Disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is an inflammatory demyelinating disorder of the central nervous system characterized by antibodies targeting myelin oligodendrocyte glycoprotein (MOG).
- Conditions
- MOGAD, Migraine, Cephalalgia
- Trial name
- MOGHEAD (NCT07479212)
- Volunteers
- 25 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Immune Thrombocytopenic Purpura
A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.
Childhood immune thrombocytopenia purpura (ITP) is a disorder characterized by the production of antibodies against platelets, resulting in enhanced destruction of platelets.
- Trial name
- NCT00376077
- Testing
- Methylprednisolone and IVIG
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- The Hospital for Sick Children
Immune Function
Effect of Fruit and Vegetable Consumption on Immune Function in the Elderly
The immune system undergoes a range of changes as individuals become elderly. These may manifest as an increasing susceptibility to infection or a tendency to develop autoimmune or malignant disease.
- Trial name
- ADIT (NCT00858728)
- Testing
- 5 portions, 2 portions
- Where
- United Kingdom
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Specific Polysaccharide Antibody Deficiency
Polysaccharide Antibody Response Study
Specific polysaccharide antibody deficiency (SPAD) is a primary immunodeficiency characterized by a deficient antibody production to capsular polysaccharides with normal total immunoglobulin levels.
- Trial name
- PARS (NCT02429531)
- Testing
- Pneumovax 23 (Sanofi Pasteur MSD), Typhim Vi (Sanofi Pasteur MSD)
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Disease, Hodgkin
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of…
- Trial name
- NCT01100502
- Testing
- brentuximab vedotin
- Where
- 87 sites in United States, Bulgaria and 11 more
- Volunteers
- 329 people
- Sponsor
- Seagen Inc.
Antiphospholipid Syndrome
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
The antiphospholipid-antibody syndrome (APLA), which includes lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoproteinI antibodies, is a thrombophilic disorder associated with arterial thrombosis, venous thrombosis or…
- Trial name
- NCT00878137
- Testing
- INR by point-of-care instruments and venopuncture
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of North Carolina, Chapel Hill
Kidney Transplantation
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
- Trial name
- NCT06365437
- Testing
- TCD601, Tacrolimus (TAC), Corticosteroids (CS)
- Where
- 7 sites in Austria, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- ITB-Med LLC
X-linked Hypophosphatemia
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab…
- Trial name
- NCT03920072
- Testing
- Burosumab
- Where
- 10 sites in France, Ireland and 2 more
- Volunteers
- 35 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Healthy Volunteers
A Study of TAK-881 in Healthy Adults
The main aims of this study are to check for side effects from TAK-881 in healthy adults and to learn how much TAK-881 they can receive without getting side effects from it.
- Trial name
- NCT05059977
- Testing
- TAK-881
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.